Evocutis welcomes Senior Non-Executive Director, Dr Gwyn Humphreys, as interim CEO.

Dr Jones is to stay at Evocutis until a new CEO is appointed.

Significant revenue increase in the first half-year reflects the progress being made in commercialising new and existing technology platforms

We have been accepted as a member of the In Vitro Testing Industrial Platform (IVTIP) and look forward to supporting its work in promoting alternatives to animal testing.

We now have a highly defined panel of 36 strains of Propionibacterium acnes to improve the reliability of testing for developers of anti-acne and blemish-reduction products.

The value of LabSkin(TM) as a marketing tool has been enhanced through its validation for use in supporting anti-ageing product claims.

Results of resolutions announced

New facilities integrate with LabSkin(TM) models for animal-free testing of ingredients and products on skin structure